ESPE Abstracts

FDA licensed the use of human recombinant growth hormone (hGH) in girls with Turner Syndrome (TS) in 1997 as short stature is a consistent feature of this syndrome.

Objective: we aimed to assess our 1-year experience of treating short girls with TS, to calculate their growth velocity, to analyze the patients’ characteristics and to investigate the possible factors that might affect their height gain.

Methods: we studied a cohort of 190 girls with TS. Anthropometric measurements were reported regularly for one year. The cost in dollars for height gain in (cm) in one year was identified using Markov cost-effectiveness simulation model.

Results: This retrospective study included 190 girls with TS (their age at the start of the study was 11.99±3.24 years. Mosaic TS represent 47 patients (24.7 %) & 60% (114) of total patients were dysmorphic, 70% of our cases had 45+X0 karyotyping & 24.7% had 45+X/46+XX karyotyping & 5.3% had other different karyotyping (45, X/47, XXX). Peak GH by Clonidine and Insulin 5.62 ± 4.82 and 8.69 ± 2.39 respectively. The predicted adult height of the first visit, last visit & delta predicted adult height between the first & last visit in our study (143.33 ± 6.59, 145.45 ± 4.67 & 2.12 ± 2.06 respectively). The cost in dollars for height gain in (cm) in one year was identified to be 99.07 ± 37.83 dollars/cm, the height gain in 1 year 5.04 ± 1.62 cm/year costed a total of 499.34 ± 190.71 dollars with hGH dose of 0.04 ± 0.01 mg/kg/d (1.36 ± 0.52 mg/day). Positive correlation between height gain during the study period and duration of therapy and height at presentation SDS (P-values = 0.027 and 0.015 respectively) and negative correlations with age at diagnosis and dose of hGH (mg/kg/d) (P- values = 0.006 and 0.02 respectively) were detected. Conclusion: hGH is effective in height and growth velocity improvement of short girls with TS. Height at presentation SDS and hGH dose seem to be effective predictors for height gain in our girls with TS.